The immunotherapy firm is conducting a Phase III trial centered on an innovative approach to treating recurrent glioblastoma, an aggressive brain cancer.
Ockham has expanded its oncology trial services offering through its acquisition of Nexus Oncology.
J&J hunting for new CMO for Doxil
Supplies of Johnson & Johnson’s Doxil cancer drug will be cut down in coming months as the company transitions to a new manufacturer.
US-based START open Phase I cancer research center in Shanghai
Anti-cancer clinical trial specialist, South Texas Accelerated Therapeutics (START), has collaborated with China's largest cancer hospital to open a new Phase I cancer research center.
Sareum sees hike in share prices thanks to inhibitor
Shares in drug discovery company Sareum have soared by 36 per cent after the firm announced the selection of a preclinical development candidate for its Checkpoint kinase 1 (Chk1) inhibitor programme.
vivoPharm branch out in US with MPI partnership and new Hershey office
vivoPharm has extended its oncology offering after striking up an alliance with MPI Research.
Synteract says the use of non-validated data systems in clinical trials is a key driver for the ‘rescue study’ segment of the contract research sector.
SCM Pharma teams with SEP in cancer product manufacturing deal
UK-based contract manufacturing organisation (CMO) SCM Pharma has struck a deal with urology experts Speciality European Pharma (SEP) to help bring SEP's oncology product, Plenaxis, to the European market.
Changing Times: The Need For a Logical Sourcing Strategy
Sponsors need to abandon the ‘single trial, random, tactical sourcing approach’ in favour of a model flexible enough for a variety of study designs and research needs according to Eli Lilly experts Lee Scheible and Jeffrey S Kasher in this exclusive guest...
Veeda Oncology launches virtual trial management service for cancer clinics
US-based Veeda Oncology has launched a new service designed to help community cancer practices manage clinical trials.
Quintiles in genomics partnership with PGT
Quintiles has signed a deal with Population Genetics Technologies (PGT) that, it says, will bring large-scale genomics analysis into the drug development mainstream.
Quintiles backs I-SPY-2 breast cancer trial
Quintiles has leant its support to I-SPY 2, an innovative clinical trial designed to accelerate the development of treatments for breast cancer.
VisualSonics unveils ‘revolutionary’ Vevo LAZR imaging system
VisualSonics, a high-resolution micro imaging systems manufacturer, has launched a new imaging system it claims will revolutionise cancer research.
Aptiv Solutions and Cancer Genetics team on cancer trial services
Aptiv Solutions and Cancer genetics have partnered to provide biopharmaceutical developers with support for cancer trials.
UK CROs extend preclinical cancer partnership
Preclinical Oncology Services Limited (Precos) will to work with discovery services firm Argenta Discovery on cancer drug development projects under a revised collaboration agreement announced late yesterday.
Kancera buys CRO iNovacia
Sweden-based cancer drug specialist Kancera has bought Stockholm-headquartered discovery and development services provider iNovacia.
Late-stage cancer trials are the biggest challenge for pharmaceutical and biotech firms according to data presented at the Biotechnology Industry Organisation's (BIO) CEO and investor conference in Washington DC, US this week.
Pool of US cancer investigators needed to boost recruitment
A pool of research-aware US oncology clinical investigators must be developed to ensure patient recruitment rates meet demand.
Ohio site joins US Oncology Research Phase I network
US Oncology Research has added a site in Dayton, Ohio, US to its network of Phase I cancer research centres.
The Christie cancer centre in Manchester, UK, has opened a £35m (€41m) early phase clinical trial unit to help develop new treatments for a range of cancers.
PBS-Bio inks deals to speed up cancer drug development
Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
Horizon and Cylene to better patient selection in cancer drug development deal
Horizon Discovery will use its X-MAN human disease cell line models to identify patients likely to benefit from Cylene Pharmaceuticals’ candidate cancer drug, CX-4945.
CRL expands cancer model offering with p53 and BCrp rats
Charles River Laboratories (CRL) has added two new exclusive knockout rats to its preclinical development offering in deal with Transposagen Biopharmaceuticals.
Chinese cancer drug brings HUYA and Quintiles together
HUYA Bioscience International will co-develop a new Chinese cancer drug, HBI-8000, with Quintiles for the “benefit of cancer patients globally.”
CRO Quintiles says biomarkers give insight into cancer drug candidates’ efficacy earlier in the development process, reducing trial costs and duration.
BNC lands cancer drug formulation contract
Bio Nano Consulting (BNC) says University of London School of Pharmacy deal helped land first Ph I trial formulation services contract.
FDA issues cancer vaccine trial guidance
Clinical trials of cancer vaccines should enrol patients with no evidence of residual disease, according to FDA guidance, but this will increase development times compared to cytotoxic agents.